Document and Entity Information - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Jun. 30, 2026 |
Sep. 17, 2026 |
Dec. 31, 2025 |
|
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Amendment Flag | false | ||
| Document Period End Date | Jun. 30, 2026 | ||
| Document Fiscal Year Focus | 2026 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Registrant Name | Neuphoria Therapeutics Inc. | ||
| Entity Central Index Key | 0001191070 | ||
| Securities Act File Number | 001-41157 | ||
| Entity Tax Identification Number | 99-3845448 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Current Fiscal Year End Date | --06-30 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Shell Company | false | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Entity Ex Transition Period | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Address, Address Line One | 14 Milliston Road | ||
| Entity Address, Address Line Two | Box 195 | ||
| Entity Address, City or Town | Millis | ||
| Entity Address, State or Province | MA | ||
| Entity Address, Postal Zip Code | 02054 | ||
| City Area Code | 339 | ||
| Local Phone Number | 240-6066 | ||
| Title of 12(b) Security | Common Stock, $0.00001 par value per share | ||
| Trading Symbol | NEUP | ||
| Security Exchange Name | NASDAQ | ||
| Entity Common Stock, Shares Outstanding | 5,411,334 | ||
| Entity Public Float | $ 7,017,007 | ||
| Auditor Firm ID | 392 | ||
| Auditor Name | Wolf & Company P.C. | ||
| Auditor Location | Boston, Massachusetts | ||
| Auditor Opinion [Text Block] | Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Neuphoria Therapeutics Inc. (the Company) as of June 30, 2026, and 2025, the related consolidated statements of operations and other comprehensive income (loss), changes in shareholders’ equity, and cash flows for each of the two years in the period ended June 30, 2026, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2026 and 2025, and the results of its operations and its cash flows for each of the two years in the period ended June 30, 2026, in conformity with accounting principles generally accepted in the United States of America. |
||
| Documents Incorporated by Reference [Text Block] | DOCUMENTS INCORPORATED BY REFERENCE List hereunder the following documents if incorporated by reference and the Part of the Form 10-K (e.g., Part I, Part II, etc.) into which the document is incorporated: (1) Any annual report to security holders; (2) Any proxy or information statement; and (3) Any prospectus filed pursuant to Rule 424(b) or (c) under the Securities Act of 1933. The listed documents should be clearly described for identification purposes (e.g., annual report to security holders for fiscal year ended December 24, 1980). |